Latest Conference Articles

PARP inhibitors are anything but dead as breast cancer treatment, argued Patricia LoRusso, DO. 

Endocrine therapy has come a long way as a treatment for breast cancer since tamoxifen ruled the adjuvant therapy landscape in 1989, but much remains unknown about newer therapies and combating endocrine resistant mutations<br /> &nbsp;

Hope S. Rugo, MD, discusses&nbsp;immunotherapies, androgen receptor (AR)-targeted agents, and targeted therapies all on the horizon in TNBC.

Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.

Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD.&nbsp;The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.

Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on &ldquo;Breast Pathology for the Non-Pathologist&rdquo; at the 18^th annual Lynn Sage Breast Cancer Symposium in Chicago.<br /> &nbsp;

The selection process for determining which procedure to utilize for an image-directed core breast biopsy often remains a mystery to those outside of the pathology and radiology world.

William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.

In an era of simultaneous increased evaluative testing in the United States and a rise in early-stage breast cancer diagnosis, it&rsquo;s important that those facing treatment decisions for curable cancer understand the advances and advantages in precision medicine, explained Steven J. Katz, MD, MPH.

Steven Katz, MD, professor, internal medicine, at the University of Michigan Medical School, discusses the major advances in precision medicine in the field of breast cancer.

Marco Davila, MD, PhD, medical oncologist, Moffitt Cancer Center, discusses MDS as an immunoresponsive disease and applying immunotherapies to MDS.

With a number of effective targeted therapies now available for patients with myeloproliferative neoplasms and chronic myeloid leukemia, patient selection for transplantation should rely heavily on prognostic scoring.

When it comes to managing high-risk patients with essential thrombocythemia (ET) or polycythemia vera (PV), John Mascarenhas, MD, starts with risk stratification.

Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses questions that still need to be answered in the myelofibrosis field.

According to Ruben A. Mesa, MD, developing a treatment plan for myelofibrosis (MF) patients who fail ruxolitinib requires an understanding of both current treatment options and those that are expected to become available within the next several years.

Zeev Estrov, MD, professor of medicine, MD Anderson Cancer Center, discusses the next steps in myelofibrosis research.

Immunotherapy offers promise in acute myeloid leukemia (AML), a disease type which has not seen significant progress in many years, said Naval G. Daver, MD, Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center.

Individualized treatment for Waldenstr&ouml;m&#39;s macroglobulinemia (WM) has become a feasible strategy with&nbsp;improved understanding of the disease and expanded treatment options.

As molecular and genetic studies have provided new insights into myelodysplastic and myeloproliferative neoplasms (MDS/MPN),&nbsp;diagnostic criteria and therapeutic strategies for the diseases continue to evolve.

According to a small study reported at the 2016 Society of Hematologic Oncology annual meeting, almost&nbsp;90% of patients with previously treated light chain amyloidosis responded to single-agent daratumumab (Darzalex).

Therapies currently available to patients with myelofibrosis offer meaningful clinical benefits, but achieving remission will likely require new molecules targeting different pathways

Lenalidomide (Revlimid) has provided evidence of potential to improve survival and reduce the leukemic progression in patients with 5q-deletion (del[5q]) myelodysplastic syndrome (MDS).

Srdan Verstovsek, MD, PhD, Chief, Section for Myeloproliferative Neoplasms at the University of Texas MD Anderson Cancer Center, Department of Leukemia, discusses identifying and treating different myeloproliferative neoplasms (MPNs).

Frankie Ann Holmes, MD, medical oncologist, Texas Oncology, discusses the implications of the results of the MA17R trial, which is a randomized phase III clinical trial that examined the benefits of extending aromatase inhibitors with letrozole as a treatment for postmenopausal patients with early breast cancer.

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering, discusses some of the emerging therapies for patients with ER-positive metastatic breast cancer.

Julia White, MD, professor of Radiation Oncology, Ohio State University, discusses some of the alternative procedures that patients with breast cancer may be able to opt for instead of whole-breast irradiation.

There is a lack of targeted agents for triple-negative breast cancer, which makes it one of the most challenging subtypes of breast cancer to treat; however, that may soon be changing.

Dual anti-HER2-directed therapies have emerged as the most beneficial neoadjuvant treatment option for patients with HER2-positive breast cancer, according to Frankie Ann Holmes, MD.

More options are now available for combining and sequencing therapy for patients with estrogen (ER)&ndash;positive metastatic breast cancer (mBC), including the deployment of CDK4/6 inhibitors, as clinicians endeavor to individualize the sequencing of therapies to improve patient outcomes, according to Maura N. Dickler, MD.